Drugs / DTwP-HepB-Hib-IPV hexavalent vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04429295 | Jun 2020 → Feb 2021 | Rotavirus infection, diphtheria, haemophilus meningitis, hepatitis B virus infection +3 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTwP-HepB-Hib-IPV hexavalent vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04429295 ↗ |
| Modality | Vaccine | “fully liquid, hexavalent, diphtheria (D)-tetanus (T)-whole-cell pertussis (wP)-inactivated poliovirus (IPV)-hepatitis B (HB)- Haemophilus influenzae b (PRP-T) vaccine” PMID 37257121 ↗ Apr 2023 |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04429295 ↗ |